Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 14, 2014
CompletedFirst Posted
Study publicly available on registry
March 18, 2014
CompletedJuly 29, 2015
July 1, 2015
March 14, 2014
July 27, 2015
Conditions
Interventions
humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
Eligibility Criteria
You may qualify if:
- Per original P05538 protocol
You may not qualify if:
- Per original P05538 protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
START
San Antonio, Texas, 78229, United States
Related Links
MeSH Terms
Interventions
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 14, 2014
First Posted
March 18, 2014
Last Updated
July 29, 2015
Record last verified: 2015-07